Plant Name: Corydalis turtschaninovii
Taxonomic Information:
Plant ID: NPO13962
Plant Latin Name: Corydalis turtschaninovii
Taxonomy Genus: Corydalis
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
1577077
Plant-of-the-World-Online:
672558-1
Used in Medicines:
Unknown.
Geographical Distribution:
China; Russia; South Africa
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR5A; ADORA2A; DRD3; ADRA1A; HTR2B; HTR2A; HTR1A; DRD1; HTR6; DRD2; ADORA3; ADORA1; | |
| TDP1; ADK; | |
| ACHE; | |
| CREBBP; | |
| LMNA; F3; SIGMAR1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.001E-13 | 1.817E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.001E-13 | 1.817E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 4.354E-13 | 4.990E-10 | ADORA1, ADORA2A, ADRA1A, DRD1, HTR1A, HTR2A, HTR2B, HTR7 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 4.180E-13 | 4.990E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR7 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.237E-12 | 1.171E-09 | ADORA1, ADORA2A, ADORA3, ADRA1A, DRD1, DRD2, DRD3, F3, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 8.113E-12 | 6.092E-09 | ADORA1, ADORA2A, ADORA3, ADRA1A, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 7.333E-10 | 4.094E-07 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.553E-09 | 8.050E-07 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 4.427E-09 | 2.008E-06 | HTR1A, HTR5A, HTR7 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 4.945E-09 | 2.153E-06 | DRD1, DRD2, DRD3, HTR2A |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 1.519E-08 | 5.804E-06 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 3.186E-08 | 1.084E-05 | ADORA1, DRD1, DRD2, HTR2A |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.865E-08 | 1.202E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 6.180E-08 | 1.869E-05 | DRD1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 9.264E-08 | 2.690E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 1.817E-07 | 4.885E-05 | DRD2, DRD3, HTR2B |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 3.145E-07 | 7.854E-05 | ADORA2A, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 3.145E-07 | 7.854E-05 | DRD1, DRD2, DRD3 |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 4.000E-07 | 9.572E-05 | ADORA1, DRD2, HTR2A |
| BP | GO:0065007; biological regulation | GO:0007202; activation of phospholipase C activity | 2.209E-06 | 4.495E-04 | ADRA1A, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 3.375E-06 | 6.024E-04 | DRD2, DRD3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.375E-06 | 6.024E-04 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0030817; regulation of cAMP biosynthetic process | 3.489E-06 | 6.060E-04 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0043266; regulation of potassium ion transport | 3.489E-06 | 6.060E-04 | ADORA1, DRD1, DRD2, HTR2A |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 3.565E-06 | 6.060E-04 | DRD2, DRD3, HTR2A |
| BP | GO:0023052; signaling | GO:0046883; regulation of hormone secretion | 7.669E-06 | 1.121E-03 | ADORA1, ADORA2A, DRD2, HTR1A, HTR2A |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.124E-05 | 1.503E-03 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 1.124E-05 | 1.503E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0042321; negative regulation of circadian sleep/wake cycle, sleep | 1.124E-05 | 1.503E-03 | ADORA1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 1.124E-05 | 1.503E-03 | HTR2A, HTR2B |
| BP | GO:0065007; biological regulation | GO:0045776; negative regulation of blood pressure | 1.237E-05 | 1.633E-03 | ADORA1, DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0043271; negative regulation of ion transport | 1.478E-05 | 1.872E-03 | ADORA1, DRD2, DRD3, HTR2A |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 1.526E-05 | 1.899E-03 | DRD2, HTR2A, HTR2B |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.856E-05 | 2.185E-03 | DRD1, DRD2, DRD3 |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 2.092E-05 | 2.423E-03 | ADORA1, ADORA2A, DRD1, DRD2 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 3.140E-05 | 3.506E-03 | DRD2, DRD3 |
| BP | GO:0008152; metabolic process | GO:0019216; regulation of lipid metabolic process | 3.621E-05 | 3.943E-03 | ADORA1, CREBBP, DRD3, HTR2A, HTR2B |
| CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 4.034E-05 | 4.223E-03 | ADORA1, ADORA2A |
| BP | GO:0009987; cellular process | GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway | 5.039E-05 | 5.080E-03 | DRD1, DRD3 |
| BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 5.039E-05 | 5.080E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 5.039E-05 | 5.080E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 5.482E-05 | 5.402E-03 | ADRA1A, DRD2, HTR2A, HTR2B |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 5.591E-05 | 5.460E-03 | ADORA1, ADORA2A, DRD2, SIGMAR1 |
| BP | GO:0032501; multicellular organismal process | GO:0007416; synapse assembly | 5.785E-05 | 5.598E-03 | ACHE, DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 6.155E-05 | 5.853E-03 | DRD2, DRD3 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 6.155E-05 | 5.853E-03 | DRD1, DRD2 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 7.381E-05 | 6.928E-03 | DRD1, DRD2 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 7.788E-05 | 7.247E-03 | ADORA1, ADORA2A, ADORA3, ADRA1A, DRD2, LMNA |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 8.718E-05 | 8.010E-03 | ADORA2A, ADRA1A |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 8.718E-05 | 8.010E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0014048; regulation of glutamate secretion | 1.016E-04 | 9.145E-03 | ADORA1, ADORA2A |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.086E-04 | 9.653E-03 | ACHE, ADORA2A, DRD2, HTR2B |
| BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 1.141E-04 | 9.974E-03 | ADORA1, ADORA2A, DRD1, DRD2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 9.595E-20 | 5.661E-18 | HTR1A, HTR2B, HTR2A, HTR5A, ADRA1A, HTR6, HTR7, ADORA2A, ADORA3, ADORA1, DRD1, DRD2, DRD3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 6.780E-12 | 2.000E-10 | HTR6, HTR7, ADORA2A, HTR2B, HTR2A, DRD1, HTR5A, ADRA1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.557E-11 | 3.062E-10 | HTR6, HTR7, CYP2D6, HTR1A, HTR2B, HTR2A, HTR5A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 8.977E-10 | 1.324E-08 | CREBBP, HTR6, ADORA2A, ADORA1, HTR1A, DRD1, DRD2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.978E-06 | 2.334E-05 | HTR2B, HTR2A, DRD1, DRD2 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 3.202E-04 | 3.149E-03 | DRD1, DRD2, DRD3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 6.809E-04 | 5.021E-03 | ADORA3, ADORA1, ADRA1A |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 4.243E-04 | 3.577E-03 | ADORA2A, DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 8.327E-04 | 5.459E-03 | ADORA2A, DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.199E-03 | 7.072E-03 | DRD1, DRD2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; DRD3; HTR1A; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| NA: NA | False perceptions | NA | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2B; HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; DRD3; HTR6; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; DRD2; |
| NA: NA | Vomiting | NA | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; HTR2A; HTR6; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; DRD3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA1A; ACHE; ADORA2A; DRD1; DRD2; ADK; HTR1A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; DRD1; DRD2; HTR1A; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRA1A; HTR1A; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | CREBBP; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ADRA1A; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1A; ADORA1; ADORA2A; DRD1; DRD2; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| NA: NA | Addiction | NA | HTR2A; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR2A; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| NA: NA | Hyperaemia | NA | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ADRA1A; DRD3; HTR1A; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; HTR2A; HTR2B; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; DRD2; DRD3; HTR2A; HTR6; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; HTR6; |
| NA: NA | Itching | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; ADRA1A; DRD2; HTR1A; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; ADORA3; |
| NA: NA | Episode | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA1A; ACHE; ADORA1; ADORA2A; ADORA3; DRD2; HTR2A; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; DRD2; HTR6; HTR1A; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; DRD2; |
| NA: NA | Social phobia | NA | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; HTR2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; ADORA3; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; HTR2A; |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADRA1A; ACHE; ADORA1; DRD1; HTR6; HTR1A; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; DRD2; |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
